Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Author:

Byrd, J.C. [etal]

Publisher:

New England Journal of Medicine

Date published:

2013

Record type:

Journal article

Journal Title:

The New England Journal of Medicine

Source:

The New England Journal of Medicine, Vol. 369, No. 1, July 4, 2013, pp. 32-42

Subject:

LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA

Abstract:

Ibrutinib inhibits Bruton's tyrosine kinase, a component of normal B-cell activation pathways. Ibrutinib produced responses in 71% of patients with refractory chronic lymphocytic leukemia.

Language:

English

Catagory URL:

http://www.nejm.org

CITATION: Byrd, J.C. [etal]. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 1, July 4, 2013, pp. 32-42 - Available at: https://library.au.int/targeting-btk-ibrutinib-relapsed-chronic-lymphocytic-leukemia-4